{
    "id": 3293,
    "fullName": "NF2 mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "NF2 mutant indicates an unspecified mutation in the NF2 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 4771,
        "geneSymbol": "NF2",
        "terms": [
            "NF2",
            "ACN",
            "BANF",
            "SCH"
        ]
    },
    "variant": "mutant",
    "createDate": "02/22/2015",
    "updateDate": "10/08/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2243,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, Tarceva (ertlotinib) treatment resulted in prolonged stable disease in 30% (3/10) of patients with NF2-related vestibular schwannoma (PMID: 20736812).",
            "molecularProfile": {
                "id": 3109,
                "profileName": "NF2 mutant"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 12689,
                "name": "acoustic neuroma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 2826,
                    "pubMedId": 20736812,
                    "title": "Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20736812"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10449,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, malignant mesothelioma cells harboring an NF2 mutation demonstrated inhibition of cell proliferation by 40% when treated with Apitolisib (GDC-0980) in culture (Mol Cancer Ther 2015;14(7 Suppl):Abstract nr A34).",
            "molecularProfile": {
                "id": 3109,
                "profileName": "NF2 mutant"
            },
            "therapy": {
                "id": 750,
                "therapyName": "GDC-0980",
                "synonyms": null
            },
            "indication": {
                "id": 1790,
                "name": "malignant mesothelioma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8464,
                    "pubMedId": null,
                    "title": "Abstract A34: GDC-0980, a dual PI3K/mTOR inhibitor, selectively inhibits NF2 mutant malignant mesothelioma (MM) cells and inhibits TOR signaling without activating Akt or ERK",
                    "url": "http://mct.aacrjournals.org/content/14/7_Supplement/A34"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2241,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Avastin (bevacizumab) improved hearing in 57% (13/23) and reduced tumor size in 55% (17/31) vestibular schwannoma patients with NF2 mutations (PMID: 22805104).",
            "molecularProfile": {
                "id": 3109,
                "profileName": "NF2 mutant"
            },
            "therapy": {
                "id": 667,
                "therapyName": "Bevacizumab",
                "synonyms": null
            },
            "indication": {
                "id": 12689,
                "name": "acoustic neuroma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2824,
                    "pubMedId": 22805104,
                    "title": "Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22805104"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17303,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Avastin (bevacizumab) and Afinitor (everolimus) combination therapy prevented additional tumor growth after 4 cycles of treatment in a patient with recurrent progressive intracranial meningioma harboring an NF2 mutation (PMID: 31043950).",
            "molecularProfile": {
                "id": 3109,
                "profileName": "NF2 mutant"
            },
            "therapy": {
                "id": 1120,
                "therapyName": "Bevacizumab + Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 3565,
                "name": "meningioma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15349,
                    "pubMedId": 31043950,
                    "title": "Everolimus and Bevacizumab in the Management of Recurrent, Progressive Intracranial NF2 Mutated Meningioma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31043950"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2068,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a rapamycin-resistant kidney cancer cell line harboring mutations in CDKN2A and NF2 demonstrated sensitivity and inhibition of MTORC1 signaling when treated with Sapanisertib (MLN0128) (PMID: 25261369).",
            "molecularProfile": {
                "id": 5001,
                "profileName": "CDKN2A mut NF2 mut"
            },
            "therapy": {
                "id": 1282,
                "therapyName": "Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2380,
                    "pubMedId": 25261369,
                    "title": "Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25261369"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2069,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) prevented cell growth and inhibited MTORC1 and MTORC2 signaling in rapamycin-resistant breast cancer cells harboring mutations in BRAF, CDKN2A, KRAS,NF2 and TP53 (PMID: 25261369).",
            "molecularProfile": {
                "id": 5003,
                "profileName": "BRAF mut CDKN2A mut KRAS mut NF2 mut TP53 mut"
            },
            "therapy": {
                "id": 1282,
                "therapyName": "Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2380,
                    "pubMedId": 25261369,
                    "title": "Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25261369"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11322,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human schwann cells harboring a NF2 mutation and expressing SH3PXD2A-HTRA1 demonstrated cell growth inhibition and abrogated expression of phosphorylated Mapk and Erk in culture when treated with Mekinist (trametinib) (PMID: 27723760).",
            "molecularProfile": {
                "id": 27959,
                "profileName": "SH3PXD2A - HTRA1 NF2 mut"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3192,
                "name": "neurilemmoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9239,
                    "pubMedId": 27723760,
                    "title": "The genomic landscape of schwannoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27723760"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17259,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, NF2 mutations were identified as acquired mutations in ctDNA of a breast cancer patient harboring ERBB2 (HER2) S310F and V777L who developed resistance to Herceptin (trastuzumab) (J Clin Oncol 37, 2019 (suppl; abstr e12518)).",
            "molecularProfile": {
                "id": 32421,
                "profileName": "ERBB2 S310F ERBB2 V777L NF2 mut"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15278,
                    "pubMedId": null,
                    "title": "Acquired NF2 mutations confer resistance to HER2 targeted therapy in HER2-mutant breast cancer.",
                    "url": "http://abstracts.asco.org/239/AbstView_239_249469.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19811,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) and Lorbrena (lorlatinib) synergistically inhibited growth of tumor cells derived from a patient with lung adenocarcinoma harboring EML4-ALK and acquired NF2 S288* and a NF2 splice site mutation (NM_000268.3:c.886-1G>A) in culture (PMID: 31585938).",
            "molecularProfile": {
                "id": 34534,
                "profileName": "EML4 - ALK NF2 S288* NF2 mut"
            },
            "therapy": {
                "id": 9225,
                "therapyName": "Lorlatinib + Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17546,
                    "pubMedId": 31585938,
                    "title": "Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31585938"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19804,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Lorbrena (lorlatinib) treatment resulted in oligo-progressive disease after 7 months of therapy in a patient with lung adenocarcinoma harboring EML4-ALK and an acquired NF2 splice site mutation (NM_000268.3:c.886-1G>A), NF2 S288* was detected in the biopsies at disease progression (PMID: 31585938).",
            "molecularProfile": {
                "id": 34534,
                "profileName": "EML4 - ALK NF2 S288* NF2 mut"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17546,
                    "pubMedId": 31585938,
                    "title": "Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31585938"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19810,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Afinitor (everolimus) and Lorbrena (lorlatinib) combination treatment inhibited growth of tumor cells derived from a patient with lung adenocarcinoma harboring EML4-ALK and acquired NF2 S288* and a NF2 splice site mutation (NM_000268.3:c.886-1G>A) in culture (PMID: 31585938).",
            "molecularProfile": {
                "id": 34534,
                "profileName": "EML4 - ALK NF2 S288* NF2 mut"
            },
            "therapy": {
                "id": 9224,
                "therapyName": "Everolimus + Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17546,
                    "pubMedId": 31585938,
                    "title": "Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31585938"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19806,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vistusertib (AZD2014) inhibited growth of tumor cells derived from a patient with lung adenocarcinoma harboring EML4-ALK and acquired NF2 S288* and a NF2 splice site mutation (NM_000268.3:c.886-1G>A) in culture (PMID: 31585938).",
            "molecularProfile": {
                "id": 34534,
                "profileName": "EML4 - ALK NF2 S288* NF2 mut"
            },
            "therapy": {
                "id": 991,
                "therapyName": "Vistusertib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17546,
                    "pubMedId": 31585938,
                    "title": "Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31585938"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19809,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vistusertib (AZD2014) and Lorbrena (lorlatinib) combination treatment inhibited growth of tumor cells derived from a patient with lung adenocarcinoma harboring EML4-ALK and acquired NF2 S288* and a NF2 splice site mutation (NM_000268.3:c.886-1G>A) in culture (PMID: 31585938).",
            "molecularProfile": {
                "id": 34534,
                "profileName": "EML4 - ALK NF2 S288* NF2 mut"
            },
            "therapy": {
                "id": 9223,
                "therapyName": "Lorlatinib + Vistusertib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17546,
                    "pubMedId": 31585938,
                    "title": "Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31585938"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19807,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vistusertib (AZD2014) inhibited growth of tumor cells derived from a patient with lung adenocarcinoma harboring EML4-ALK and acquired NF2 K543N and a NF2 splice site mutation (NM_000268.3:c.886-1G>A) in culture (PMID: 31585938).",
            "molecularProfile": {
                "id": 34536,
                "profileName": "EML4 - ALK NF2 K543N NF2 mut"
            },
            "therapy": {
                "id": 991,
                "therapyName": "Vistusertib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17546,
                    "pubMedId": 31585938,
                    "title": "Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31585938"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19805,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Lorbrena (lorlatinib) treatment resulted in multiple new lesions after 15 months of therapy in a patient with lung adenocarcinoma harboring EML4-ALK and an acquired NF2 splice site mutation (NM_000268.3:c.886-1G>A), NF2 K543N was detected in the adrenal biopsy at disease progression (PMID: 31585938).",
            "molecularProfile": {
                "id": 34536,
                "profileName": "EML4 - ALK NF2 K543N NF2 mut"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17546,
                    "pubMedId": 31585938,
                    "title": "Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31585938"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19808,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vistusertib (AZD2014) and Lorbrena (lorlatinib) combination treatment inhibited growth of tumor cells derived from a patient with lung adenocarcinoma harboring EML4-ALK and acquired NF2 K543N and a NF2 splice site mutation (NM_000268.3:c.886-1G>A) in culture, and inhibited tumor growth in patient-derived xenograft models (PMID: 31585938).",
            "molecularProfile": {
                "id": 34536,
                "profileName": "EML4 - ALK NF2 K543N NF2 mut"
            },
            "therapy": {
                "id": 9223,
                "therapyName": "Lorlatinib + Vistusertib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17546,
                    "pubMedId": 31585938,
                    "title": "Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31585938"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3109,
            "profileName": "NF2 mutant",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 5001,
            "profileName": "CDKN2A mut NF2 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 5003,
            "profileName": "BRAF mut CDKN2A mut KRAS mut NF2 mut TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27959,
            "profileName": "SH3PXD2A - HTRA1 NF2 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32421,
            "profileName": "ERBB2 S310F ERBB2 V777L NF2 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34533,
            "profileName": "EML4 - ALK NF2 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34534,
            "profileName": "EML4 - ALK NF2 S288* NF2 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34536,
            "profileName": "EML4 - ALK NF2 K543N NF2 mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}